Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
NCT04164199 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 404
Last updated 2026-05-08
Summary
This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).
Conditions
- Advanced Malignancies
Interventions
- DRUG
-
Tislelizumab
Administered intravenously.
- DRUG
-
Pamiparib
Administered orally.
- DRUG
-
Administered orally.
- DRUG
-
Sitravatinib
Administered orally.
- DRUG
-
Ociperlimab
Administered intravenously.
- DRUG
-
BAT1706
Administered intravenously.
- DRUG
-
Administered orally.
- DRUG
-
BGB-15025
Administered orally.
- DRUG
-
Administered intravenously.
- DRUG
-
BGB-A445
Administered intravenously.
- DRUG
-
Surzebiclimab
Administered intravenously.
- DRUG
-
Administered orally.
- DRUG
-
LBL-007
Administered intravenously.
Sponsors & Collaborators
-
BeOne Medicines
lead INDUSTRY
Principal Investigators
-
Study Director · BeOne Medicines
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-19
- Primary Completion
- 2026-07-31
- Completion
- 2026-07-31
- FDA Drug
- Yes
Countries
- United States
- Australia
- China
- France
- Italy
- Japan
- Malaysia
- New Zealand
- Poland
- South Korea
- Taiwan
- Thailand
- Turkey (Türkiye)
Study Locations
More Related Trials
-
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
AMT-116 in Patients With Advanced Solid Tumors
NCT05725291 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
NCT05010525 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
NCT02516553 ·Status: COMPLETED ·Phase: PHASE1
-
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
NCT04649385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
NCT03474289 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers
NCT05749549 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
NCT02407990 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
NCT01680991 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
NCT05372367 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
NCT05155332 ·Status: SUSPENDED ·Phase: PHASE1
-
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
NCT05490043 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02410512 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
NCT02712905 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02715531 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of AGEN1571 in Participants With Advanced Solid Tumors
NCT05377528 ·Status: COMPLETED ·Phase: PHASE1
-
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132 ·Status: RECRUITING ·Phase: PHASE1
-
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
NCT05327946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1